Midatech Pharma Plc (MTP)
MTP said that it has entered into a licensing agreement with Emergex Vaccines Limited, a private UK biotechnology company focused on infectious diseases.
This exclusive agreement between the companies is focused on MTP’s proprietary platform based on certain metal core glyconanoparticles and Emergex’s development and commercialisation of various vaccines, to prevent/treat infectious diseases.
According to MTP, this will be the first application of its nanoparticles within vaccines in infectious diseases and represents another step in the company’s ambitious growth strategy.
As part of the deal, MTPwill receive initial, milestone and royalty payments. The company has also agreed a Service and Manufacturing Agreement with Emergex for synthesis and for manufacturing of cGMP material for clinical trials.
Shares of MTP closed at $4.85 on the last trading session of 2015
MTP is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and three marketed products in the US.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer